@bleeleet.bsky.social
Reposted
The FDA expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said.
FDA approves standalone use of J&J’s ketamine-derived depression treatment | CNN
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company...
www.cnn.com
January 22, 2025 at 1:52 AM
The FDA expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said.